B-HT 920 - CAS# 36085-73-1 Size:Solid 2 mg Inhibition of this enzyme's activity

Inhibition of this enzyme's activity by azoles results in decreased amounts of ergosterol

ADP668 is currently under clinical trial for diabetes

Regio- and stereoselective synthesis of aminoinositols and 1

thereby preventing the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53

2014 Jul 24

B-HT 920 - CAS# 36085-73-1 Size:Solid 2 mg Inhibition of this enzyme's activityTalipexole, also known as B HT920 and Domnin, is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe. Talipexole is a D2 dopamine receptor agonist and interacts both pre and post synaptic receptors. It also is an 2 adrenergic agonist. The main side effects are drowsiness, dizziness,